AI assistant
Sending…
Sonoma Pharmaceuticals, Inc. — Director's Dealing 2012
Oct 2, 2012
35312_dirs_2012-10-02_8bd7a8e7-75d5-43e7-9f42-d0bc9fffe267.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Oculus Innovative Sciences, Inc. (OCLS)
CIK: 0001367083
Period of Report: 2012-10-01
Reporting Person: Alton Gregg H (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-10-01 | Stock Option (Right to Buy) | $0.90 | A | 15000 | Acquired | 2022-10-01 | Common Stock (15000) | Direct |
Footnotes
F1: The option will vest in equal monthly increments over a period of one year.
F2: The option was granted by the Issuer as compensation for serving on the Issuer's Board of Directors.
More from Sonoma Pharmaceuticals, Inc.
Capital/Financing Update
2026
Apr 30
Capital/Financing Update
2026
Apr 27
Capital/Financing Update
2026
Apr 17
Regulatory Filings
2026
Apr 9
Interim / Quarterly Report
2026
Feb 10
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 28
Investor Presentation
2026
Jan 12
Director's Dealing
2026
Jan 2
Director's Dealing
2026
Jan 2